Operation Warp Speed Angles For Greater Role In Pfizer COVID-19 Vaccine Manufacturing
Government offers help securing supplies in return for another 100 million doses by Q2. That would mean abandoning Pfizer’s preferred arms-length relationship.
You may also be interested in...
It’s counter-intuitive, but not signing a commercial contract with BioNTech and refusing US federal funding were two of several moves Pfizer made to speed up development of its COVID-19 vaccine, CEO Albert Bourla says. Now it’s looking to supply low- and middle-income countries.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
Rather than holding half of all vaccines produced to ensure administration of the second dose, only a portion would be held to cover for manufacturing or other problems.